Related Experiment Video
Updated: Jun 9, 2026

An Automated Method to Perform The In Vitro Micronucleus Assay using Multispectral Imaging Flow Cytometry
Published on: May 13, 2019
Immunotoxicity screening in vitro using an economical multiple endpoint approach
1Cytotest Cell Research GmbH & Co. KG (CCR), PO Box 1252, D-6101 Rossdorf, Germany.
An economical multiple endpoint in vitro test battery has been developed for screening chemically induced immune dysfunction. Bearing in mind the complexity of the immune system, different types of immunocompetent cells were used. Cofactor-fortified liver homogenate obtained from rats pretreated with Aroclor (S-9 mix) was employed as an in vitro metabolizing system. The following principal screening design was applied. Immunocompetent cells (peritoneal cells and splenocytes) obtained from female C57B(1) mice were treated in vitro for 1 hr. For metabolic activation, chemicals were pretreated with S-9 mix for 2 hr. After the incubation period the cells were washed and different immune function assays (antibody-dependent phagocytosis and lipopolysaccharide-induced release of tumour necrosis factor of thioglycollate-elicited peritoneal macrophages; natural killer cell activity, T- and B-cell blastogenesis, and B-cell antibody synthesis of spleen cell suspensions) were performed. For economy the different spleen cell functions were tested in parallel with aliquots of cells derived from the same chemically treated culture. As an additional parameter the survival of the cells was determined routinely after treatment during all assays. Different chemicals (e.g. tributyltinoxide, 7,12-dimethylbenzanthracene, lead acetate, cyclophosphamide, dexamethasone) were assessed using this system. The results indicate that the in vitro test battery described is a suitable tool for immunotoxicity screening.
An economical multiple endpoint in vitro test battery has been developed for screening chemically induced immune dysfunction. Bearing in mind the complexity of the immune system, different types of immunocompetent cells were used. Cofactor-fortified liver homogenate obtained from rats pretreated with Aroclor (S-9 mix) was employed as an in vitro metabolizing system. The following principal screening design was applied. Immunocompetent cells (peritoneal cells and splenocytes) obtained from female C57B(1) mice were treated in vitro for 1 hr. For metabolic activation, chemicals were pretreated with S-9 mix for 2 hr. After the incubation period the cells were washed and different immune function assays (antibody-dependent phagocytosis and lipopolysaccharide-induced release of tumour necrosis factor of thioglycollate-elicited peritoneal macrophages; natural killer cell activity, T- and B-cell blastogenesis, and B-cell antibody synthesis of spleen cell suspensions) were performed. For economy the different spleen cell functions were tested in parallel with aliquots of cells derived from the same chemically treated culture. As an additional parameter the survival of the cells was determined routinely after treatment during all assays. Different chemicals (e.g. tributyltinoxide, 7,12-dimethylbenzanthracene, lead acetate, cyclophosphamide, dexamethasone) were assessed using this system. The results indicate that the in vitro test battery described is a suitable tool for immunotoxicity screening.
